アブストラクト
| Title | ANCA関連血管炎 治療 |
|---|---|
| Subtitle | 特集 急速進行性腎炎症候群 - Up date 【各論】 |
| Authors | 遠藤知美** |
| Authors (kana) | |
| Organization | **田附興風会医学研究所北野病院 腎臓内科 |
| Journal | 腎と透析 |
| Volume | 91 |
| Number | 3 |
| Page | 387-392 |
| Year/Month | 2021 / 9 |
| Article | 報告 |
| Publisher | 東京医学社 |
| Abstract | 「はじめに」 ANCA(anti-neutrophil cytoplasmic antibody)関連血管炎(ANCA-associated vasculitis:AAV)は全身性の血管炎であり, 高頻度に認められる急速進行性糸球体腎炎(rapidly progressive glomerulonephritis:RPGN)のほか, 多彩な腎外病変を認める. また, わが国では高齢発症の顕微鏡的多発血管炎(microscopic polyangiitis:MPA)が多く認められるという特徴がある. それゆえ, 血管炎の活動性や腎機能障害の程度や年齢を考慮しつつ, 初発時に可能な限り副腎皮質ステロイド(corticosteroid:CS)と免疫抑制薬を併用した適切な強度の治療を施行し, 重篤な感染症を起こすことなくAAVの鎮静化を実現することが重要である. そして, 寛解導入後はCS減量を進め, 維持治療へと移行する. |
| Practice | 臨床医学：内科系 |
| Keywords | 寛解導入治療, 寛解維持治療, 副腎皮質ステロイド, シクロホスファミド, リツキシマブ |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Fujimoto S, Watts RA, Kobayashi S, et al: Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology (Oxford) 50:1916-1920, 2011
- 2) 成田一衛(監),厚生労働科学研究費補助金難治性疾患等研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班(編):エビデンスに基づく急速進行性腎炎症候群(RPGN)診療ガイドライン 2020,東京医学社,東京, 2020
- 3) Nachman PH, Hogan SL, Jennette JC, et al: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:33-39, 1996
- 4) Stone JH, Merkel PA, Spiera R, et al: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232, 2010
- 5) Jones RB, Tervaert JWC, Hauser T, et al: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211-220, 2010
残りの15件を表示する
- 6) Ntatsaki E, Carruthers D, Chakravarty K, et al: BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53:2306-2309, 2014
- 7) Yates M, Watts RA, Bajema IM, et al: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583-1594, 2016
- 8) 厚生労働省特定疾患進行性腎障害に関する調査研究班:急速進行性腎炎症候群の診療指針 第2版.日腎会誌 53:509-555, 2011
- 9) Walsh M, Merkel PA, Peh CA, et al: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382:622-631, 2020
- 10) Smith RM, Jones RB, Specks U, et al: Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79:1243-1249, 2020
- 11) Han F, Liu G, Zhang X, et al: Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol 33:185-192, 2011
- 12) Jones RB, Hiemstra TF, Ballarin J, et al: Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78:399-405, 2019
- 13) Muso E, Ito-Ihara T, Ono T, et al: Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 57:S17-18, 2004
- 14) Ito-Ihara T, Ono T, Nogaki F, et al: Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 102:c35-42, 2006
- 15) Guillevin L, Pagnoux C, Karras A, et al: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771-1780, 2014
- 16) Terrier B, Pagnoux C, Perrodeau E, et al: Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77:1151-1156, 2018
- 17) Walsh M, Merkel PA, Mahr A, et al: Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 62:1166-1173, 2010
- 18) Smith RM, Jayne DRW, Merkel PA: Abstract number 806: A randomized, controlled trial of Rituximab versus Azathioprine after induction of remission with Rituximab for patients with ANCA-associated vasculitis and relapsing disease. ACR/ARP Annual Meeting, Atlanta, Nov 10, 2019 https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/
- 19) Charles P, Terrier B, Perrodeau E, et al: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77:1143-1149, 2018
- 20) Wechsler ME, Akuthota P, Jayne D, et al: Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921-1932, 2017
